Oncology ImagingArchives
ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer
Oncology Imaging 1 min.
Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that...
A rare primary mediastinal mesenchymal tumor diagnosed by endobronchial ultrasound (EBUS)
Oncology Imaging 2 min.
Mesenchymal tumors of the mediastinum are exceedingly rare, accounting for only approximately 2–6% of all mediastinal neoplasms [1]. Except for certain exceptions, mediastinal soft tissue tumors display histological and molecular features largely analogous to those of their counterparts in other...
Machine learning-DeepSurv prediction model integrating mpMRI radiomics and genomic biomarkers for BCR-free survival and tumor response in prostate radiotherapy
Oncology Imaging 1 min.
The purpose of this study was to design a radiogenomics machine learning-DeepSurv model for biochemical recurrence-free (BCR-free) survival and treatment response (TR) prediction for radiotherapy (RT) of prostate cancer (PCa). In this study, radiomic features were extracted from pre and post treatment...
Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis
Oncology Imaging 4 min.
Breast cancer (BC) is the second most common malignant neoplasm globally, and it ranks fifth as a cause of death [1]. Neoadjuvant chemotherapy (NAC) can reduce patient’s primary tumor burden and the extent of nodal involvement, which may increase the likelihood of breast-conserving surgery and...
A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer
Oncology Imaging 5 min.
Breast cancer is a prevalent malignant tumor among women worldwide, accounting for 11.6% of new cases annually [1]. Human epidermal growth factor receptor 2 (HER-2) is a significant factor influencing the prognosis of patients with breast cancer. It is a crucial gene target for breast cancer treatment...
